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BACKGROUND: Regional anaesthesia in the form of Brachial plexus
block is an attractive option when compared to General anaesthesia, since it
has the advantages of post-operative pain relief as well as decreased nausea
and vomiting. This makes regional anaesthesia the preferred technique in
day care surgery. Axillary plexus block is one of the most commonly
performed regional nerve block for upper limb surgeries. The proximity of
the nerves of brachial plexus to the axillary artery makes the identification
of structures easy with both nerve stimulator and ultrasound guided block.
AIM: To compare the analgesic efficacy of dexmedetomidine added to
bupivacaine, lignocaine with adrenaline mixture versus bupivacaine,
lignocaine with adrenaline mixture alone in axillary plexus block for upper
limb surgeries.
METHODS: This study is a prospective randomized controlled study.
The study involved 60 patients. They were randomly divided into two
groups, Group RD received axillary plexus block with 50 microgram
of dexmedetomidine added to local anaesthetic mixture and Group
RL received axillary plexus block with local anaesthetic mixture
alone. Both the groups were followed up for the onset of sensory and motor
blockade and the duration of analgesia using the Visual Analog Scale score.
RESULTS: Both the study and control groups were comparable in terms of
age, height, weight and BMI. The mean arterial pressure of the patients in
the dexmedetomidine group was 80.27 ± 6.39 mmHg whereas the mean
arterial pressure in the control group was 97.47 ± 8.16 mmHg at the 45th
minute. The mean pulse rate of the patients in the dexmedetomidine group
was around 70 bpm and around 85 bpm in the control group but none of the
patients required atropine. The onset time of sensory block in the
dexmedetomidine group was found to be 9.37 ± 1.7 minutes whereas in the
control group it was found to be 15.83 ± 1.18 minutes. The onset time of
motor block in the dexmedetomidine group was found to be 12.23 ± 1.85
minutes whereas in the control group it was found to be 18.77 ± 1.22
minutes. The mean duration of analgesia in the dexmedetomidine group was
found to be 16.53 ± 1.41 hours whereas the mean duration of analgesia in
the control group was found to be 9.70 ± 1.44 hours.
CONCLUSION: Dexmedetomidine in the dose of 50 microgram when
added as an adjuvant to local anaesthetic mixture in axillary plexus block
had a faster onset of sensory, motor block and significantly prolonged the
duration of analgesia. They caused a minimal decrease in the mean arterial
pressure and heart rate which did not warrant treatment.
KEY WORDS: Dexmedetomidine, axillary block, Visual Analog Scale
(VAS)
1INTRODUCTION
Regional anaesthesia in the form of Brachial plexus blocks is an
attractive option when compared to General anaesthesia, since it has the
advantages of post-operative pain relief as well as decreased nausea and
vomiting. This makes regional anaesthesia the preferred technique in
day care surgery(1).
Axillary plexus block is one of the most commonly performed
regional nerve block for upper limb surgeries(2).  The  proximity  of  the
nerves of brachial plexus to the axillary artery makes the identification
of structures easy with both nerve stimulator and ultrasound guided
block.
Brachial plexus can be approached by any of the four techniques
– inter-scalene approach, supra-clavicular approach, infra-clavicular
approach and axillary approach(3). Brachial plexus block is performed by
placing the tip of the needle close to the nerves of the plexus and
injecting the local anaesthetic solution.
The  axillary  plexus  block  is  the  safest  of  the  four  approaches  to
the brachial plexus(4). It does not cause pneumothorax or phrenic nerve
palsy caused by the other approaches of brachial plexus block. It has
2many advantages over general anaesthesia like reduced risk of
aspiration, increased post-operative pain relief and decreased post-
operative opioid requirements.
Axillary plexus block was described by Halstead in 1884(5). It can
be used for surgeries involving the elbow, forearm and hand surgeries
providing excellent analgesia and anaesthesia(6).
Local anaesthetic combinations of lignocaine with adrenaline and
bupivacaine are injected into the axillary sheath to provide axillary
plexus blockade. Different agents have been tried as adjuvants, added to
the local anaesthetics to fasten the onset and prolong the duration of
sensory and motor blockade. Some of the agents which have been
studied are Dexamethasone, Fentanyl, Midazolam, Buprenorphine,
Tramadol and Clonidine.
Alpha – 2 agonists like clonidine and dexmedetomidine have
multiple benefits like analgesia, anaesthesia, sedation and
sympatholysis. Dexmedetomidine is a centrally acting, selective alpha –
2 adrenergic agonist and is more potent than clonidine(7).
3Dexmedetomidine produces sedation, anxiolysis(8), decreases
anaesthetic requirement and maintains good hemodynamic stability
intraoperatively. When a low dose of dexmedetomidine is added to the
local anaesthetic mixture, it provides a faster onset of sensory and motor
blockade and prolongs the duration of sensory and motor blockade
without much hemodynamic instability.
Dexmedetomidine has different mechanisms of action(9) like:
1. Direct action on peripheral nerve
2. Central action and
3. Attenuation of inflammatory response.
In this study we investigated the addition of dexmedetomidine as
an adjuvant to the local anaesthetic mixture in axillary plexus block, in
comparison with local anaesthetic mixture alone in order to evaluate the
beneficial effects of dexmedetomidine.
Aim of the Study
4AIM OF THE STUDY
The  aim  of  the  study  was  to  compare  the  analgesic  efficacy  of
dexmedetomidine added to bupivacaine, lignocaine with adrenaline
mixture versus bupivacaine, lignocaine with adrenaline mixture alone in
axillary plexus block for upper limb surgeries.
Objectives
5OBJECTIVES
The Objective of the study was to compare the
1. Onset of sensory and motor blockade and
2. Duration of analgesia between the two groups of patients who
underwent upper limb surgeries under axillary block, with or
without Dexmedetomidine.
Review of Literature
6REVIEW OF LITERATURE
C A Mackay and D F Bowden(10) conducted a study in 1997 titled
“Axillary brachial plexus block--an underused technique in the accident
and emergency department”. The main objective of the study was to
compare the axillary plexus block with Bier’s block for providing upper
limb analgesia. Patients posted for elective upper limb procedures were
given either axillary plexus block or Bier’s block. Axillary block was
performed with either perivascular or trans-arterial technique and the
patients received 40ml of 1% lignocaine with adrenaline. Bier’s block
was  performed  with  a  single  cuff  tourniquet  and  received  3mg/kg  of
0.5% prilocaine. Seventy five patients were included in the study. 39
patients received axillary plexus block and 36 patients Bier’s block. The
onset  of  anaesthesia  was  slower  with  axillary  block  group.  But  the
duration of analgesia and patient satisfaction was more with axillary
block group.
O’Donnell BD et al(11) conducted a study in 2009 named,
“Ultrasound-guided axillary brachial plexus block with 20 millilitres
local anesthetic mixture versus general anaesthesia for upper limb
trauma surgery: an observer-blinded, prospective, randomized,
controlled trial”. The study was a randomised double blind controlled
7study. The patients were randomised into two groups either ultrasound
guided axillary block or general anaesthesia. Ultrasound guided axillary
plexus block was performed using needle out of plane approach and 5ml
of local anaesthetic mixture containing 2% lignocaine with adrenaline,
0.5% bupivacaine and 75microgram/ml of clonidine was injected in the
respective nerve distributions of medial, ulnar, radial and
musculocutaneous nerves. General anaesthesia was induced with
fentanyl and propofol, maintained with O2/N2O/Sevoflurane mixture.
Visual Analog pain scores were lower in patients who were given ultra-
sound guided block. The patients had satisfactory anaesthesia and earlier
discharge in the ultra-sound guided nerve block group.
Fatma Nur Kaya et al(12) conducted a study in 2009 regarding the
effect of intra-venous dexmedetomidine in prolonging bupivacaine
spinal anaesthesia. It was a double blinded randomised placebo
controlled study. After obtaining written informed consent, seventy five
patients classified under the ASA I and II category and undergoing
TURP surgery under spinal anaesthesia were included in the study.
After insertion of an 18gauge intra-venous catheter, the patients were
divided into three groups – group one received 0.5microgram/kg of
dexmedetomidine intravenously, group two received 0.05mg/kg of
8midazolam intravenously and group three received physiological saline.
Bupivacaine 0.5% 3ml was injected intrathecally. Sensory block was
higher with dexmedetomidine group. Time for sensory regression of two
dermatomes was longer with dexmedetomidine. Dexmedetomidine
increased the time to first request of analgesic and the maximum
Ramsay sedation score attained was greater with dexmedetomidine than
with midazolam or saline.
Imasogie N(13) conducted a study in 2010 titled “A prospective,
randomized, double-blind comparison of ultrasound-guided axillary
brachial plexus blocks using 2 versus 4 injections”. The study was a
randomised double blind controlled study. One hundred and twenty
patients posted for elective upper limb surgeries were divided into two
groups.  Group  I  received  axillary  plexus  block  with  a  2  point  skin
puncture, 30ml of 0.5% ropivacaine was injected posterior to the
axillary artery and the remaining 10ml of local anaesthetic for the
musculocutaneous nerve. Group II received 40ml of 0.5% local
anaesthetic using separate 10ml injections to the radial, ulnar, median
and musculocutaneous nerves. The 2 – point injection technique was
faster to administer. But the percentage of patients with complete block
at 30minutes and the block success rate were similar in both the groups.
9Hala S. Abdel-ghaffar(14) performed a study in 2011 regarding the
effect of “Efficacy and safety of intraoperative dexmedetomidine in
pediatric posttonsillectomy pain: Peritonsillar versus intravenous
administration”. The study design was a prospective randomised
controlled double blind study. Eighty four children in the age group 5-
12 years of age posted for elective tonsillectomy procedures were
included in the study. After obtaining approval from the Institutional
Ethical committee and written informed consent from the legal
guardians, the children were divided into three groups using computer
generated random numbers.
? Group I (DEX IV) – received 1microgram/kg of
dexmedetomidine intravenously diluted in 50ml of 0.9% normal
saline infused over 10minutes after induction of anaesthesia.
? Group II (DEXPT) – received 1microgram/kg of
dexmedetomidine diluted in 4ml of 0.9% normal saline given by
peritonsillar infiltration after intubation of trachea.
?  Group III (Placebo) – received 50ml of 0.9% normal saline
intravenous infusion and 4ml of 0.9% normal saline peritonsillar
infiltration.
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Anaesthesia was induced with propofol 2-3mg/kg and atracurium
0.5mg/kg given to facilitate endotracheal intubation. No NSAIDs,
opioid, paracetamol or additional propofol were given during the
procedure. Neuromuscular reversal done with neostigmine 0.05mg/kg
and atropine 0.02mg/kg and the children were extubated awake after
return of protective airway reflexes. They were then placed in the post-
tonsillectomy recovery position. The time to extubation was
significantly prolonged in group DEX IV. The time to first analgesic
requirement was also significantly prolonged in group DEX IV and
DEXPT. The mean usage of paracetamol rescue analgesia was
significantly lower in group DEX IV and DEXPT. The mean sedation
scores were significantly higher in group DEX IV. The request for more
than one analgesic dose was higher in the Placebo group.
Hala  E  A  Eid  MD(15) conducted a study regarding the effect of
dose related prolongation of spinal anaesthesia with the addition of
dexmedetomidine to hyperbaric bupivacaine. Forty eight adult patients
under the ASA I and II physical status scheduled for elective anterior
cruciate ligament repair were included in the study. They were
randomised into three equal groups – group D1 received 3ml of 0.5%
hyperbaric bupivacaine and 10microgram of dexmedetomidine, group
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D2 received 3ml of 0.5% hyperbaric bupivacaine and 15microgram of
dexmedetomidine, group B received 3ml of 0.5% bupivacaine and
normal saline. The time to 2-segment regression and sensory regression
was significantly prolonged in both the dexmedetomidine groups. The
post-operative pain scores were significantly reduced in groups D1 and
D2. The post-operative Ramsay sedation scores were also significantly
increased in the dexmedetomidine groups.
D.  Marhofer  et  al(16)  performed a study in 2012 regarding the
effect of dexmedetomidine when added to ropivacaine as an adjuvant to
prolong peripheral nerve blockade. After obtaining approval from the
Ethical committee and getting informed consent, thirty six adult patients
in the age group 18 – 45 years planned for volunteer controlled study
with an ultra-sound guided ulnar nerve block were included in the study.
Patients with anatomical abnormalities of the forearm, obesity (BMI >
30Kg/m2), coagulopathy and known allergy to local anaesthetics were
excluded from the study. After starting an intra-venous cannula,
ultrasound visualisation of the ulnar nerve was done and ulnar nerve
block was performed (UNB).
? Ropivacaine (R group) – received 3ml of 0.75% ropivacaine plus
0.2ml of saline and iv 5ml of saline.
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? Ropivacaine plus peri-neural dexmedetomidine (RpD) – received
3ml of 0.75% ropivacaine plus 20microgram of dexmedetomidine
and iv 5ml of saline.
? Ropivacaine with systemic dexmedetomidine (RsD) – received
3ml of 0.75% ropivacaine plus 0.2ml of saline and 20microgram
of dexmedetomidine mixed with 4.8ml of saline iv.
The onset of sensory block was not statistically significant
between the three groups. The onset time of motor block was
significantly faster in the group RpD (perineural dexmedetomidine). The
duration of sensory and motor blockade was significantly increased
when 20microgram of dexmedetomidine is added peri-neurally or
systemically.
H. Kang et al(17) conducted a study in 2012 regarding the effect of
dexmedetomidine when added to pre-emptive ropivacaine infiltration
for post-operative pain after inguinal herniorrhaphy. Fifty two adult
male patients posted for elective hernia repair were randomly allocated
into two groups. Group RO patients received 10ml infiltration of 0.2%
ropivacaine to skin 2minutes prior to skin incision and group RD
patients received 10ml infiltration of 0.2% ropivacaine with
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1microgram/kg of dexmedetomidine via the same technique. All the
patients were given general anaesthesia. Induction was done with
5mg/kg of thiopental iv and 0.6mg/kg of rocuronium iv. The trachea
was intubated and maintained with O2 : N2O – 1.5 : 1.5 and sevoflurane
2 – 3%. All the surgeries were carried out by the same surgeon. The
primary outcomes were the VAS pain scores, amount of fentanyl
consumption and the frequency to push button (FPB) in the PCA
system. The total amount of fentanyl consumption and the frequency to
push button was significantly decreased in the group RD as compared
group RO.
Kenan Kaygusuz, MD et al(18) conducted a study on 2012. They
studied “The effect of adding dexmedetomidine to levobupivacaine in
axillary brachial plexus block”. Sixty four patients with ASA I & II
physical status posted for forearm and hand surgeries with axillary
plexus block were included. They were randomly divided into two
groups (n = 32) – group L and group D.  Group L patients received 39ml
of 0.5% levobupivacaine with 1ml of isotonic saline and Group D
patients received 39ml of 0.5% levobupivacaine with 1ml of
dexmedetomidine 1microgram/kg. Hemodynamic parameters like mean
arterial blood pressure, heart rate and peripheral oxygen saturation was
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noted throughout the procedure. The onset times of sensory and motor
block was significantly decreased in the group D compared to group L.
The duration of sensory and motor block and the time to first analgesic
use was significantly increased in group D compared to group L. The
total need for analgesics was also significantly decreased in the group D.
Ahmed Sobhy Basuni(19) performed a study in 2013 regarding the
effect of addition of dexmedetomidine to low dose levobupivacaine
spinal anaesthesia for knee arthroscopy surgeries. The study design was
a prospective randomised controlled double blind study. Sixty adult
patients of both the sexes under the ASA physical status I and II posted
for knee arthroscopy surgeries were included in the study. Patients were
randomised into two groups using computer generated random numbers.
? Group D – received 5mg of 0.5% levobupivacaine and
3microgram of dexmedetomidine intrathecally.
? Group F – received 5mg of levobupivacaine and
10microgram of fentanyl intrathecally.
Prior to subarachnoid block, monitors like electrocardiography,
pulse oximetry and non-invasive blood pressure were connected and
baseline values recorded. The patients were pre-loaded with 250ml of
15
Ringer Lactate solution. Subarachnoid block was performed with
25gauge Quincke’s needle at the L3-4 space in the sitting position with
the bevel facing up. The onset of sensory block, the time to highest
sensory block and the time to highest Bromage score were faster in
group D. The duration of sensory block and the intensity of motor block
were superior in group D as compared to group F.
Ji Eun Kim and Na Young Kim(20) published a study in 2013
regarding the effects of addition of dexmedetomidine to low dose
bupivacaine spinal anaesthesia in elderly patients undergoing
transurethral prostatectomy. Fifty four elderly patients posted for
transurethral prostatectomy was included in the study. Using computer
generated random numbers they were divided into two groups.
? Group  S  –  received  6mg  of  0.5%  bupivacaine  with  0.3ml  of
dexmedetomidine (3 microgram)
? Group D – received 6mg of 0.5% bupivacaine with 0.3ml of
preservative free normal saline.
Prior to spinal anaesthesia, the patients were hydrated with 300 ml
of 0.9% normal saline. During the surgical procedure, the fluid was
minimally infused to avoid overloading. Spinal block was performed at
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L3 – L4 space with a 25gauge Quincke’s needle with the patient in the
lateral  decubitus  position.  The  end  points  of  the  study  were  time  to  2
segment regression of the sensory dermatomes from the peak sensory
level. The values of Mean arterial pressure and Heart rate were not
significantly different between the two groups despite the patients being
elderly. The time to reach the peak sympathetic and sensory block was
significantly shorter in group D. The time to 2 segment regression of
sensory dermatomes was significantly longer in group D and the
requirement of post-operative analgesics were significantly shorter in
group D as compared to group S.
B. Maharani and M. Sathya Prakash(21) conducted a study in 2013
comparing the addition of dexmedetomidine or buprenorphine as
adjuvants to spinal anaesthesia. Sixty adult patients posted for infra-
umbilical and lower limb surgeries under the ASA physical status I and
II were included in the study. They were randomly divided into two
groups
? Group A – received 15mg of 0.5% bupivacaine plus
10microgram of dexmedetomidine intrathecally.
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? Group B – received 15mg of 0.5% bupivacaine plus
60microgram of buprenorphine intrathecally.
Addition of dexmedetomidine to bupivacaine significantly
decreased the onset time of sensory blockade, prolonged the duration of
sensory and motor blockade and the time for first analgesic requirement.
Waleed A. Almarakbi and Abdullah M. Kaki(22) conducted a study
in 2014 regarding the effect of addition of dexmedetomidine to
bupivacaine in transverse abdominis plexus block in prolonging post-
operative pain relief. After approval from Institutional ethical committee
and obtaining informed consent, 50 patients over the age of 18years
under the ASA physical status I and II scheduled for abdominal
hysterectomy were included in the study. During the pre-operative
assessment, the Visual Analog Scale for pain assessment with 0
meaning no pain and 10 meaning worst pain was explained to the
patient. Inj. Midazolam 0.03mg/kg was given 15 minutes prior to
induction of anaesthesia. General anaesthesia was standardised in both
the patient groups. Fentanyl 2microgram/kg, propofol 2mg/kg and cis-
atracurium 0.1mg/kg was given for tracheal intubation. Anaesthesia was
maintained with O2/Air/Sevoflurane mixture. Randomisation was done
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using computer generated software into two equal groups. Transverse
abdominis block was performed in both the groups.
? Group B – received 20ml of 0.25% bupivacaine plus 2ml of
normal saline
? Group BD – received 20ml of 0.25% bupivacaine plus 2ml of
normal saline with 0.5 microgram/kg of dexmedetomidine
The post-operative requirement of morphine and time to first
analgesic requirement was noted. The total dose of morphine required
was significantly lower in group BD. The time to first analgesic
requirement was also significantly longer in group BD as compared to
group B.
Saumya Biswas and Ratan Kumar Das(23) conducted a study in
2014 regarding the effect of dexmedetomidine as an adjuvant added to
levobupivacaine in supraclavicular brachial plexus block. After Ethical
committee approval and obtaining informed consent, sixty patients
under the ASA physical status I and II scheduled for elective forearm
and hand surgeries were included in the study. They were divided into
two groups of thirty patients each using computer generated random
numbers.
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? Group  L  –  received  35ml  of  levobupivacaine  0.5%  and  1ml  of
normal saline
? Group LD – received 35ml of levobupivacaine 0.5% and 1ml of
dexmedetomidine (100microgram)
On arrival to the operating room, baseline monitors of BP, SpO2
and HR were recorded. An intra-venous line was started with an
18gauge cannula and infusion of Ringer lactate started. The systolic and
diastolic pressures were significantly lower in group LD than in group
L. Sensory and motor block duration were significantly longer in group
LD as compared to group L.
Yu Zhang et al(24) performed a study in 2014 regarding
“perineural administration of dexmedetomidine in combination with
ropivacaine prolongs axillary brachial plexus block”. The study was a
prospective, randomized controlled double blind trial. Forty five adult
patients in the age group 25 – 60 years of age posted for elective
forearm and hand surgeries were included in the study after obtaining
Ethical committee approval and informed consent. Patients were divided
into three groups –
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? Group R – received 40ml of 0.33% ropivacaine along with
1ml of normal saline.
? Group DR1 – received 40ml of 0.33% ropivacaine along
with 1ml of dexmedetomidine (50microgram)
? Group DR2 – received 40ml of 0.33% ropivacaine along
with 1ml of dexmedetomidine (100microgram)
Standard monitoring was attached and a 20guage peripheral
cannula was inserted in the contra-lateral arm. Using nerve stimulator
technique, three point axillary plexus block was performed – radial or
ulnar, median and musculocutaneous nerve. Thirteen millilitres of local
anaesthetic was injected in the site of radial or ulnar and median nerve
respectively. Nine millilitres of solution was injected in the musculo-
cutaneous nerve distribution and the remaining six millilitre was
injected in the skin subcutaneously to block the intercosto brachial
nerve. The onset time of sensory and motor blockade was not
significantly different in the three groups. The duration of sensory
blockade was significantly increased in the group DR2 than the other
groups. The incidence of side effects was also higher in the DR2 group
(hypotension, bradycardia). Bradycardia was treated with atropine
injection.
21
Samy E. Hanoura et al published their study in 2015. They
conducted the study “dexmedetomidine improves the outcome of a
bupivacaine brachial plexus axillary block: a prospective comparative
study”. After obtaining informed consent, patients in the age group 23 –
56 years under the ASA physical status I & II posted for elective
orthopaedic upper limb surgeries were included in the study. The
patients were divided into equal groups –
? Group D – received axillary block with 40ml of 0.25%
bupivacaine and 1ml of dexmedetomidine (100microgram)
? Group B – received axillary block with 40ml of 0.25%
bupivacaine and 1ml of normal saline.
The axillary block was performed using nerve stimulator
technique. The parameters like block performance time, latency time,
duration of sensory and motor block and duration of analgesia were
noted. The severity of pain assessed using the Visual Analog Scale
(VAS) over a 10 point scale. The latency time was statistically shorter in
the group D compared to group B. The duration of motor block was not
statistically different and the duration of sensory block was significantly
longer in the group D compared to group B.
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Vinod Hosalli and Anilkumar Ganeshnavar conducted a study in
2015. They compared the addition of dexmedetomidine or clonidine to
levobupivacaine in ultrasound guided axillary plexus block. After
obtaining informed consent, sixty ASA physical status I & II patients
undergoing bony orthopaedic procedures in the upper limb were
selected for the study. The patients were randomly divided into 2 groups
by slips in the box technique.
? Group C – received 36ml of 0.5% levobupivacaine and
1microgram/kg of clonidine.
? Group D – received 36ml of 0.5% levobupiacaine and
1microgram/kg of dexmedetomidine.
The patients were taken to the operating room and the baseline
values of heart rate, blood pressure and Electrocardiography were
recorded. The axillary block was performed with the ultrasound system.
6ml of local anaesthetic was injected to anaesthetise the
musculocutaneous nerve. The radial, ulnar and median nerve were
anaesthetised with 10ml of local anaesthetic each. There was no
significant difference in the onset times of sensory and motor block in
the two groups. The duration of sensory and motor block was
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significantly longer in the group D compared to group C. Pulse rate,
Systolic and diastolic pressure was significantly lower in group D
compared to group C.
Don Sebastian and Ravi M(25) conducted a study in 2015
comparing the addition of dexmedetomidine or clonidine to ropivacaine
in supraclavicular plexus block. The study was a randomised double
blind controlled study. After obtaining Ethical committee approval and
informed consent, sixty adult patients in the age group 18 – 55 years
under the ASA physical status I and II were included in the study. They
were randomly divided into two groups using computer generated
numbers.
? Group C – received 29ml of 0.5% ropivacaine with 1ml of
clonidine (50microgram)
? Group D – received 29ml of 0.5% ropivacaine with 1ml of
dexmedetomidine (50microgram)
On arrival to the operating room, intravenous line started with an
18gauge intra-venous cannula and Ringer lactate infusion was started.
Basic monitors of heart rate, blood pressure and haemoglobin oxygen
saturation were connected. The supra-clavicular block performed with
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the classical nerve stimulator technique. The current stimulation was
started with a stimulation intensity of 2.0mA and pulse width of 100ms.
Once the desired response was attained, current was gradually reduced
till  0.4mA  and  the  drug  solution  injected  if  the  desired  response
persisted. There were no significant difference in the general
characteristics of the patient like age, weight or height. The onset of
sensory block and motor block was significantly shorter in group D
compared to group C. The duration of sensory block and motor block
was significantly longer in group D.
Hem Anand Nayagam, N Ratan Singh and H Shanti Singh(26)
conducted a study in 2015 regarding the effect of addition of fentanyl
and dexmedetomidine to low dose bupivacaine heavy in spinal
anaesthesia. The study was a prospective randomised double blind
controlled study. 150 patients were selected after approval from the
Institutional Ethical committee and obtaining informed consent. They
were randomly divided into two groups by computer generated random
numbers.
? Group F – received 0.8ml of 0.5% bupivacaine heavy with 0.5ml
of 25microgram fentanyl and 0.3ml of normal saline intrathecally.
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? Group D – received 0.8ml of 0.5% bupivacaine heavy with
0.05ml of 5microgram dexmedetomidine and 0.75ml of normal
saline intrathecally.
The time to reach the T10 sensory segment was not significantly
different between the two groups. The time to reach peak sensory level
was significantly faster in group D. The total analgesic requirements
was also significantly lesser in group D.
Ay?e Ülgey et al conducted a study regarding the “The Analgesic
Effects of Incisional Levobupivacaine with Dexmedetomidine after
Total Abdominal Hysterectomy”. Fifty adult patients posted for elective
hysterectomy under the ASA physical status I and II were included in
the study. The patients after obtaining informed consent were divided
into two equal groups – group L received 40ml of 0.25%
levobupivacaine infiltration of the surgical area and group LD received
40ml of 0.25% levobupivacaine and 2microgram/kg dexmedetomedine
5minutes prior to surgical incision. The rescue analgesic requirement
was significantly lower in group LD. The Visual Analog Scale at 0, 2
and 4 hours were significantly less in group LD as compared to group L.
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SS  Harsoor  et  al(27) conducted a study in 2015 regarding the
“Effect of supplementation of low dose intravenous dexmedetomidine
on characteristics of spinal anaesthesia with hyperbaric bupivacaine”.
After obtaining informed consent, fifty adult patients posted for elective
lower abdominal and lower limb surgeries were included in the study.
They were randomly divided into two groups – group D received
0.5microgram/kg of dexmedetomidine intravenous bolus given
10minute prior to subarachnoid block and then 0.5microgram/kg/hour
till the duration of surgery and group C received similar volumes of
normal saline. They concluded that administration of dexmedetomidine
intravenously fastens the onset of sensory blockade and prolongs the
duration of sensory and motor blockade.
Alpha 2 Adrenergic
Receptors
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ALPHA – 2 ADRENORECEPTOR
The primary sympathetic neurotransmitters nor-adrenaline and
adrenaline exert their central and peripheral actions through specialised
receptors called adrenergic receptors.
Adrenergic receptors are present in nearly all the peripheral
tissues and in the central nervous system neurons. Three types of
adrenergic receptors are present – alpha 1, alpha 2 and alpha 3(28). They
belong to the cell surface G-protein coupled type of receptors.
Alpha 2 receptors are subdivided into three subtypes alpha 2A,
alpha 2B and alpha 2C(29).
1. Alpha 2A – gene on chromosome 10 and involved in sedation and
analgesia
2. Alpha 2B – gene on chromosome 4 and involved in hemodynamic
effects
3. Alpha 2C – gene on chromosome 2
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ALPHA – 2 AGONISTS
Since 1970s, alpha 2 adrenergic agonists have been used for the
treatment of hypertension and for drug withdrawal. Alpha 2 agonists
produce diverse responses like analgesia, anxiolysis, sedation and
sympatholysis.
Recently the Food and Drug Administration approved the usage
of two novel alpha 2 agonists – clonidine and dexmedetomidine for the
usage in Intensive Care Unit sedation. Its use has now been investigated
as  an  adjuvant  to  prolong  the  effects  of  epidural,  spinal  and  peripheral
nerve blocks.
MECHANISM OF ACTION:
1. Inhibits the adenylate cyclase enzyme(30) responsible for the
production of 3,6 – cyclic adenosine monophosphate resulting in
decreased availability of cyclic AMP. Cyclic AMP mediates
phosphorylation of many of the intra-cellular target proteins. This
results in hyper-polarisations of the neuronal cell membrane
which results in decreased firing rate of excitable cells.
29
2. N-type voltage gated calcium channels are inhibited resulting in
decreased entry of calcium ions which results in decreased
catecholamine secretion.
3. Activates the alpha 2 adrenoreceptor in the pre-synaptic region
resulting in decreased release of sympathetic neurotransmitters.
 Dexmedetomidine produces all these effects by their multiple
mechanisms of action and thereby avoiding multiple pharmacology and
their combined side effects.
There is no clear mechanism by which the alpha 2 agonists
produce analgesia. Possible mechanisms may be supra-spinal effect in
the locus ceruleus and spinal effects in the substantia gelatinosa
resulting in the production of analgesia.
On addition of dexmedetomidine, the excitable nerve cells can
neither fire nor propagate the signal to the neighbouring cells resulting
in analgesia by central, spinal and peripheral actions.
The ratio of alpha 2 : alpha 1 activity for dexmedetomidine is
1620 : 1 and 220 : 1 for clonidine. Hence dexmedetomidine is a more
selective alpha 2 adrenergic agonist than clonidine.
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Pharmacology of
Dexmedetomidine
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PHARMACOLOGY OF DEXMEDETOMIDINE
Dexmedetomidine is the S-enantiomer of medetomidine(31), used
widely in the veterinary practice. Chemically Dexmedetomidine is
(S)-4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole.
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PHARMACOKINETICS
ABSORPTION:
Dexmedetomidine is inactive orally and the conventional route of
administration is the intra-venous route. Dexmedetomidine has good
bio-availability with nasal, intra-muscular, buccal, sublingual, neuraxial
and intra-articular routes.
DISTRIBUTION:
Elimination half life          -      2-3 hours
Volume of distribution      -      118 litres
PROTEIN BINDING:
Dexmedetomidine is 95% protein bound to albumin. Protein
bound fraction decreases with hepatic impairment. Dexmedetomidine
does not displace phenytoin, propranolol, warfarin, digoxin and
theophylline from plasma proteins.
METABOLISM:
Biotransformation occurs in the liver to inactive metabolites.
Metabolism occurs by N-methyl glucuronidation in the liver and the
glucuronide metabolites are excreted in the urine. Hence the dosage of
dexmedetomidine must be decreased in patients with hepatic failure.
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ADDITIONAL BENEFITS:
Dexmedetomidine has antisialagogue, antishivering and
decongestant properties. Dexmedetomidine has minimal respiratory
depression compared to other drugs with a better hemodynamic
stability.
ADVERSE EFFECTS:
The most notable side effects of dexmedetomidine are
bradycardia, hypotension, dry mouth, nausea and vomiting. Transient
hypertension can be seen in large doses and sudden discontinuation can
lead to a withdrawal syndrome with agitation, irritability and
hypertensive  crisis.  It  is  classified  as  a  Category  C  drug  in  pregnancy
(Animal studies have observed risk but well controlled human studies
not available).
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PHARMACODYNAMICS
EFFECTS ON THE CARDIOVASCULAR SYSTEM:
Dexmedetomidine causes a dose dependent inhibition of the
vasomotor centre leading to bradycardia and hypotension.
Dexmedetomidine is not a myocardial depressant. On administration, a
biphasic response in BP occurs – an initial hypertensive phase due to
peripheral alpha 2B receptor activation and a subsequent hypotensive
phase due to presynaptic alpha 2A receptor activation.
EFFECTS ON THE RESPIRATORY SYSTEM:
Dexmedetomidine has no significant effects on the respiratory
system and respiratory depression does not occur.
EFFECTS ON THE CENTRAL NERVOUS SYSTEM:
Dexmedetomidine decreases cerebral excitation, decreases
cerebral blood flow and cerebral metabolic oxygen demand thus
maintaining the balance between cerebral oxygen demand and supply.
EFFECT ON GENITOURINARY SYSTEM:
Dexmedetomidine decreases renin release, increases glomerular
filtration rate and increases sodium and water excretion by their action
on the peripheral alpha 2 receptors.
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CLINICAL USES
ATTENUATION OF STRESS RESPONSE:
Dexmedetomidine decreases the stress responses to tracheal
intubation at a dose of 1 microgram / kg.
AS AN ANAESTHETIC ADJUVANT TO GENERAL ANAESTHESIA:
Dexmedetomidine decreases the anaesthetic requirements of all
the volatile anaesthetics and opioid analgesics resulting in their
decreased usage.
AS AN ADJUVANT TO NEURAXIAL ANAESTHESIA:
Dexmedetomidine at a dose of 5 microgram when added
intrathecally to hyperbaric 0.5% bupivacaine can prolong the post-
operative analgesia
AS AN ADJUVANT TO PERIPHERAL NERVE BLOCK:
Dexmedetomidine when added to bupivacaine at a dose of 0.5
microgram / kg can prolong the duration of analgesia
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IN MONITORED ANAESTHESIA CARE:
Dexmedetomidine can be used for procedures like fibre-optic
bronchoscopy, dental procedures and ophthalmic procedures with
decreased opioid requirements and better post-operative outcome.
SEDATION IN INTENSIVE CARE UNIT:
The sedation produced by dexmedetomidine mimics normal sleep
with minimal respiratory depression, decreased agitation and good
hemodynamic stability.
Pharmacology of
Bupivacaine
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PHARMACOLOGY OF BUPIVACAINE
Bupivacaine is an amide group of long acting local anaesthetic. It
was synthesized in 1957 by A. F. Ekenstam.
It is produced as a racemic mixture containing equal quantities of
S  and  R enantiomers.  It  is  supplied  as  a  hydrochloride  salt  for  clinical
usage.
CHEMICAL NAME:
(2S)-1-Butyl-N-(2,6-dimethylphenyl)-piperidinecarboxamide
CHEMICAL STRUCTURE:
38
PHYSIO-CHEMICAL PROPERTIES:
Molecular weight - 290 gm/mol
pKa - 8.1
Solubility in water - 1 in 25
Solubility in alcohol - 1 in 8
Octanol/water partition coefficient - high
Lipid solubility - 28
Plasma protein binding - 95%
MECHANISM OF ACTION:
Local anaesthetics produce blockade of sodium channels
resulting in decreased sodium entry into the cells thereby preventing the
depolarisation of the cells. Thus the nerve signals and the action
potential cannot be propagated.
PHARMACOKINETICS:
Bupivacaine is rapidly absorbed from the injection site. The
rate of rise of plasma concentration and the peak plasma concentration
attained depends on the route of administration. Inter-individual
variability occurs in the time taken to attain the peak plasma
concentration and can vary from 5 – 30 minutes after the drug
administration.
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Steady state volume of distribution - 70 litres
Clearance - 0.48 L/min
Alpha t ½ - 2.8 min
Beta t ½ - 28 min
Gamma t ½ - 3.5 hours
METABOLISM:
Bupivacaine can undergo any one of the following metabolic
pathways – aromatic hydroxylation, N-methyl dealkylation, amide
hydrolysis and conjugation. The metabolites of bupivacaine are
excreted in the liver and hence renal disease does not affect the
metabolism of bupivacaine. The fraction of drug excreted unchanged in
urine is less than 10 %.
ONSET OF ACTION IN NERVE BLOCKS - 15 – 20minutes
DURATION OF ACTION IN NERVE BLOCKS  - 8 – 10hours
The pKa or the dissociation constant is defined as the pH at which
50% of the drug is ionised and 50% of the drug is in the unionised form.
A drug having a pKa close to the physiological pH will have more drug
in the unionised form. The unionised fraction is the easily diffusible
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form of the drug. Hence a drug having more unionised form of drug at
physiological pH will be faster acting.
Bupivacaine has a clinical profile different from that of
lignocaine. It has a pKa of 8.1 and has slower onset of action compared
to lignocaine. But it is 4 times more potent than lignocaine and the
sensory block produced by bupivacaine is more marked.
CLINICAL USES:
? Central neuraxial anaesthesia
? Peripheral nerve blocks
? Infiltration anaesthesia
PREPARATIONS:
? 0.25%, 0.5% Solutions available in 10 and 20ml vials.
? 5mg/ml of 0.5% bupivacaine and 80mg of dextrose in 4ml
ampules for intrathecal injection.
CONTRAINDICATIONS:
? History of hypersensitivity to amide local anaesthetics
? Intravenous regional anaesthesia
? Paracervical block
Pharmacology of
Lignocaine
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PHARMACOLOGY OF LIGNOCAINE
Lidocaine is an amide group of local anaesthetics. Lidocaine was
discovered in 1943 by Nils Lofgren and then on is in routine usage.
CHEMICAL FORMULA:
2-(diethylamino)-N-(2, 6 dimethylphenyl)acetamide
CHEMICAL STRUCTURE:
PHYSIO-CHEMICAL PROPERTIES:
Molecular weight                       -                   234gm/mol
pKa - 7.6
Lipid solubility - less than bupivacaine
Plasma protein binding - 60-80%
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MECHANISM OF ACTION:
Lidocaine acts in the similar way as all the local anaesthetics act
by blocking the fast voltage gated sodium channels located in the
neuronal cell membranes resulting in decreased action potential
propagation.
PHARMACOKINETICS:
On entering the circulation, lidocaine is 60 – 80% plasma protein
bound.
Volume of distribution - 1-2L/min
Elimination half life - 90-120mins
METABOLISM:
Lidocaine is principally metabolised by N-dealkylation in the
liver via the CYP3A4 metabolic pathway. It is converted into mono-
ethylglycinexylidide which is pharmacologically active and then to
glycinexylidide which is inactive. Most of the metabolites are excreted
in the urine.
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ONSET OF ACTION - 45-90seconds
DURATION OF ACTION - 10-20minutes
The pKa of lidocaine is 7.6 and is close to the physiological pH
and has more number of unionised drug at the site of action and hence
has a faster onset of action compared to bupivacaine.
PREPARATIONS:
Intravenous – 2% and 1% solutions with or without adrenaline
Topical gel/patches – 5% lidocaine
Topical sprays – 10% lidocaine
CLINICAL USES:
? Central neuraxial anaesthesia
? Peripheral nerve blocks
? Infiltration anaesthesia
? Anaesthesia for airway procedures like Fibre Optic
Bronchoscopy
Adverse effects of
Local Anaesthetics
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ADVERSE EFFECTS OF
LOCAL ANAESTHETICS:
Adverse effects are due to excess plasma concentrations of the
drug which can be due to over-dosage of the drug, unintentional intra-
vascular injection of the drug or slower rate of degradation.
ALLERGIC REACTIONS:
The presence of rash, utricaria and laryngeal edema is highly
suggestive of bupivacaine induced allergic reaction. It can be due to the
preservative methylparaben used with the local anaesthetics. Cross
sensitivity among the different groups of local anaesthetics has been
reported.
CENTRAL NERVOUS SYSTEM REACTIONS:
Low plasma concentrations characteristically produces numbness
of  the  tongue  and  the  circumoral  regions.  As  the  plasma concentration
increases the patient exhibits restlessness, slurred speech, skeletal
muscle twitching and progresses to tonic-clonic seizures. Seizures are
followed by CNS depression accompanied with hypotension.
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CARDIO-VASCULAR SYSTEM REACTIONS:
Local anaesthetics can produce cardiac sodium channel blockade
resulting in cardiac dysarrhythmias, atrio-ventricular block, ventricular
tachycardia and ventricular fibrillation. After an accidental intravascular
injection, the protein binding sites are fully saturated resulting in large
amount of the unbound fraction of the drug available for binding to the
conducting tissues of the heart. Pregnancy may increase the sensitivity
of the cardiotoxic effects of local anaesthetics.
TREATMENT OF SYSTEMIC TOXICITY OF LOCAL
ANAESTHETICS:
? The treatment is primarily supportive. Stop administration of the
local anaesthetic injection immediately.
? Airway, breathing and circulation must be maintained.
? Avoid hypoxia, hypercapnia and acidosis.
? Benzodiazepines can be given for the prevention and treatment of
seizure activity.
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? Sympathomimetic agents like ephedrine and epinephrine,
defibrillators and amiodarone must be available for cardiovascular
complications.
? Lipid  emulsions  by  acting  as  a  plasma  sink.  The  bolus  dose  of
lipid emulsion is 1.5ml/kg of 20% solution followed by an
infusion of 0.25ml/kg/minute for 10minutes.
Anatomy of
Brachial Plexus
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ANATOMY OF BRACHIAL PLEXUS
FORMATION:
The  brachial  plexus  is  formed  by  the  anterior  rami  of  the
nerve roots C5 – 8 and T1. There may be contributions above from C4
(pre-fixed) and below from T2 (post-fixed). These variations are
associated with either the presence of a cervical rib or an anomalous
1st rib.
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The roots of the plexus C5-C8 & T1 emerge from the inter-
vertebral foramina. The nerve roots of C5, C6 and C7 pass behind the
foramen transversarium of their respective cervical vertebra and then
lies between the anterior and posterior tubercles of the respective
transverse process. Then the nerve roots lies between the scalenus
anterior and medius.
The roots of the C5 and C6 unite to form the upper trunk, C7
nerve root continues as the middle trunk and C8 and T1 unite to form
the lower trunk. The brachial plexus lies between two sheaths of fibrous
tissue formed form the posterior and anterior tubercles such that the
local anaesthetic is injected in this sheath to produce a brachial plexus
block.
The  trunks  then  pass  downward  and  laterally  at  the  base  of  the
posterior triangle and across the base of the first rib. Trunks divide into
an  anterior  division  and  posterior  division  at  the  lateral  border  of  the
first rib.
The divisions then divide to form the three cords – lateral, medial
and posterior. They are named in relation to the axillary artery. The
lateral cord is formed by the anterior division of the upper and lower
trunks. The medial cord is formed by the continuation of the anterior
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division of the lower trunk. The posterior cord is formed by the
posterior divisions of all the three trunks.
The branches of the lateral cord are:
? Lateral pectoral nerve (C5 – C7)
? Lateral root of median nerve(C5 – C7)
? Musculocutaneous nerve (C6, 7)
The branches of the medial cord are:
? Medial pectoral nerve (C8, T1)
? Medial cutaneous nerve of arm (C8, T1)
? Medial cutaneous nerve of forearm (C8, T1)
? Medial head of median nerve (C8, T1)
? Ulnar nerve (C7 – 8, T1)
The branches of the posterior cord are:
? Upper subscapular nerve (C5, C6)
? Nerve to lattismus dorsi
? Lower subscapular nerve (C5, C6)
? Axillary nerve (C5, C6)
? Radial nerve (C5 – 8, T1)
Brachial Plexus Blocks
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BRACHIAL PLEXUS BLOCKS
The choice of the brachial plexus block depends on the desired
site to be blocked and the risk of pneumothorax that accompanies the
clavicular approaches.
INTERSCALENE BLOCK:
The brachial plexus is blocked at the level of upper trunk at the
level of the sixth cervical vertebra. The space between the anterior and
middle scalene muscles is the inter-scalene groove and the needle is
inserted in the groove at right angles. Paraesthesia can be elicited or
contractions in the deltoid or biceps brachialis muscle can be elicited by
nerve stimulator technique.
Blockade of the cervical sympathetic chain or the phrenic nerve
commonly occurs and are accompaniments of the block. Complications
include accidental intra-vascular, epidural or subarachnoid injections.
They are less effective for surgeries of the hand as the lower trunks are
not blocked.
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SUBCLAVIAN PERIVASCULAR APPROACH:
Subclavian perivascular approach targets the brachial plexus as it
crosses over the 1st rib. Used to provide analgesia of the whole arm, can
be occasionally deficient over the territory supplied by the ulnar nerve.
The inter-scalene groove at the level of 6th cervical vertebra is identified
and followed down to the neck and the needle entry is made just
posterior to the subclavian artery pulsation.
Any periclavicular approach is associated with a risk of
pneumothorax due to puncture of the pleura. In order to avoid the risk of
pneumothorax, the 1st rib is used as a backstop.
AXILLARY BRACHIAL PLEXUS BLOCK:
Axillary plexus block targets the terminal branches of the brachial
plexus mainly radial, ulnar and median nerves as they enter the axilla
along with the axillary artery. The block is not useful for surgeries of the
shoulder or upper arm as the nerves supplying them have already left the
plexus at this point.
Axillary block is most appropriate for surgeries involving the
elbow, forearm and hand. The axillary artery is palpated as high up in
the axilla and fixed throughout the procedure. A single injection
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technique or a multiple injection technique can be performed. In
multiple injection technique, individual nerves are identified and 10ml
of the local anaesthetic is injected around each nerve.
Materials and Methods
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MATERIALS AND METHODS
 “Prospective randomized controlled study evaluating
dexmedetomidine as an adjuvant added to a local anaesthetic mixture of
bupivacaine, lignocaine with adrenaline in axillary plexus block as
compared to axillary plexus block with local anaesthetic mixture alone”
Was duly submitted before the Institutional Ethical Committee
and after getting approval from the ethical committee the study was
done on 60 patients.
STUDY DESIGN:
The study design was a Prospective Randomized Controlled
study.
SAMPLE SIZE CALCULATION:
 The study population consisted of 60 adult patients classified
under the ASA 1 or 2 posted for upper limb surgical and orthopaedic
procedures below the mid-humerus level.
INCLUSION CRITERIA:
? 18 – 60 years of age
? ASA physical status 1 or 2
? Patients undergoing elbow, forearm and hand surgeries
? Patients who gave valid informed consent
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EXCLUSION CRITERIA:
? Lack of written informed consent
? Patients with diabetes and renal disease
? Pregnancy
? Patients with baseline heart rate less than 60bpm
? Patients on sedatives, opioids in the week prior to surgery
STUDY CENTRE:
? ESIC MEDICAL COLLEGE & PGIMSR, KK NAGAR over a
period of ten months.
PRE-OPERATIVE ASSESSMENT:
All  the  patients  were  duly  examined  on  the  day  before  surgery
and pre-operative assessment chart was checked. Any specific
complaints of the patient like pain, anxiety must be sought out. The
height and weight of the patient was measured. The airway assessment
and the nutritional status of the patient was examined.
All the systems were examined in detail. All the pre-operative
investigations like complete blood count, haematocrit, renal function
tests, blood grouping and typing, chest radiography and
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electrocardiography were evaluated and the risk was stratified based on
American Society of Anaesthesiologist’s grading.
INFORMED CONSENT:
All the patients satisfying the inclusion criteria were explained
about the nature of this study and a written valid informed consent was
obtained from all the patients.
PRE-MEDICATION:
All the patients were kept nil per oral for 8 hours and were pre-
medicated with tablet alprazolam 0.5mg, tablet ranitidine 150mg and
tablet metoclopramide 10mg on the night prior to surgery.
PREPARATION:
All the patients on arrival into the operating room,
electrocardiography, pulse oximetry and non-invasive blood pressure
monitors were connected and basal parameters recorded. An intra-
venous access with 18 gauge cannula was started. Patients were
randomly allocated into either of the two groups – group RD or group
RL by slips in the box technique.
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MATERIALS:
DRUGS
? IV Dexmedetomidne
? 0.5% bupivacaine
? 2% lignocaine with adrenaline
? Emergency resuscitation drugs
EQUIPMENTS
? Insulated stimulator needle
? Peripheral nerve stimulator
? ECG electrode
? Two 20ml(Luerlock) syringes
? One tuberculin syringe of 1ml
? Two stainless sterile bowls on each for iodine and spirit
? Sterile gauze pieces
? Equipment for administration of General Anaesthesia, if required.
MONITORS
? ELECTROCARDIOGRAPHY
? PULSE OXIMETRY
? NON – INVASIVE BLOOD PRESSURE
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TECHNIQUE:
AXILLARY PLEXUS BLOCK (Nerve Stimulator technique)
The patient is placed in the supine position with the head facing
opposite to the side being blocked. The arm is abducted to 90 degrees.
Axilla was aseptically cleaned and draped. The operator stood on
the side to be blocked so that for a left side block the palpation was done
with the left hand and the needle is manipulated with the right and the
operator stands on the left side.
The axillary artery is palpated as high up in the axilla and is fixed
firmly against the humerus between the index and middle finger of the
palpating hand. The artery is fixed firmly throughout the procedure.
Local infiltration of 1ml of 2% lignocaine given.
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An insulated needle will be used to perform this technique.  The
needle is connected to nerve locator by the electrodes and is properly
grounded with the help of ECG leads.
Group RD receives 20ml of 0.5% bupivacaine, 10ml of 2%
lignocaine with adrenaline and 1ml of 50microgram dexmeditomidine.
Group RL receives  20ml  of  0.5%  bupivacaine,  10ml  of  2%
lignocaine with adrenaline and 1ml of normal saline.
The stimulation is started with an intensity of 2.0 mA and a pulse
width of 100 microseconds. Once the skin is entered, the needle is
inserted to a depth of 1 -2 cm below the artery until a desired response –
extension of wrist and fingers are obtained. 10 – 15ml of local
anaesthetic is injected after negative aspiration of blood.
The needle is then withdrawn upto the skin and inserted above the
artery until the response – flexion of the fingers and wrist is obtained.
The needle is inserted till further until the median nerve twitch appears.
5 – 10 ml of local anaesthetic is injected after negative aspiration of
blood
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The needle is then inserted into the bulk of coracobrachialis till
the biceps branchii twitch occurred and the remaining 5 – 10ml of local
anaesthetic is injected.
As  a  goal  we  decided  to  elicit  an  isolated  muscle  twitch  in  the
fingers either in flexion or extension for the desired response. Wrist
flexion and extension of fingers is taken as the acceptable response and
the current is gradually reduced till the twitch appears above 0.5 mA. 3
minute massage is done to facilitate an even drug distribution.
BLOCK EVALUATION:
Sensory block is assessed using pinprick method using the end of
a 27guage needle at 0, 2, 5, 10, 15, 20 and 30 minutes in the median,
ulnar, radial and musculocutaneous nerve distribution.
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GRADES OF SENSORY BLOCKADE:
GRADE 0        - Sharp pain felt
GRADE 1 - Analgesia, dull sensation felt
GRADE 2 - Anaesthesia, no sensation felt
Motor block is evaluated using Modified Bromage scale at 0, 10,
20 and 30 minutes.
GRADES OF MOTOR BLOCAKDE:
GRADE 0  - Normal motor function with full flexion and extension of
elbow, wrist and fingers.
GRADE 1  – Decreased motor strength with ability to move the fingers
only.
GRADE 2  – Complete motor block with inability to move the fingers.
ONSET TIME:
The  onset  time  of  sensory  and  motor  blockade  is  defined  as  the
time interval between the end of local anaesthetic injection and
? Loss of sensation to pin prick (sensory score – 1)
? Paresis (motor scale – 1) in the distribution of all peripheral
nerves respectively.
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Surgery is allowed to proceed when complete anaesthesia is
achieved. Post-operative follow up is carried out in the recovery and
post-operative ward for the Visual Analog score.
The patients were explained about Visual Analog Scale in the pre-
operative assessment and the VAS scores were subsequently assessed in
the post-operative period. VAS score of 4 indicated moderate pain and
the rescue analgesic is administered at a VAS score of 4 or more.
VAS SCORE 0 – 2 - No pain
VAS SCORE 2 – 4 - Mild pain
VAS SCORE 4 – 6 - Moderate pain
VAS SCORE 6 – 8 - Severe pain
VAS SCORE 8 – 10 - Unbearable pain
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PATIENT FLOW CHART
Patients pre-operatively assessed and
posted for elective upper limb surgeries
Informed written consent obtained
Patient taken to the operating room
WHO checklist carried out
Groups randomized by Slips in the box technique
Pulse Oximetry, Electrocardiography,
Non-invasive blood pressure monitors connected
Axillary block performed using the nerve stimulator technique
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Group RD :
? Bupivacaine 0.5% (20ml)
? Lidocaine with adrenaline
2%(10ml)
? Dexmedetomidine 50mcg (1ml)
Group RL :
? Bupivacaine 0.5% (20ml)
? Lidocaine with adrenaline
2%(10ml)
? Normal saline (1ml)
Block assessment :
Sensory block       -      Pin prick method
Motor block          -      Modified Bromage scale
Post – operative follow up    -    Duration of analgesia
Results and Statistics
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RESULTS AND STATISTICS
Sixty patients were included in the study and they were
randomised by slips in the box technique into two groups – 30 patients
belonged to the study group and 30 patients belonged to the control
group. The demographical characteristics of the two groups were
studied and found no significant difference between the two groups in
terms of age,@ body mass index.
TABLE-1 : AGE DISTRIBUTION
Age Group
GROUP-RD GROUP-RL
No of
Patients
( N )
Percentage
( % )
No of
Patients
( N )
Percentage
( % )
20 – 30 8 26.67 17 56.67
31 – 40 10 33.33 4 13.33
41 – 50 10 33.33 8 26.67
51 – 60 2 6.67 1 3.33
TOTAL 30 100 30 100
Chi square
value
6.37
p-value 0.10
Significant Not  Significant
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GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
Both the groups are similar in distribution in term of age.
Mean Age (in Years)
Group Mean Standard Deviation
GROUP-RD 37.60 10.07
GROUP-RL 33.13 9.99
t-value 1.73
p-value 0.09
Significant Not Significant
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TABLE-2 : SEX DISTRIBUTION
Sex
GROUP-RD GROUP-RL
No of
Patients
( N )
Percentage
( % )
No of
Patients
( N )
Percentage
( % )
Male 25 83.33 24 80.00
Female 5 16.67 6 2.00
TOTAL 30 100 30 100
Chi square
value 0.11
p-value 0.74
Significant Not  Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
No statistically significant difference in sex distribution between
the groups.
67
TABLE-3 : Weight Distribution
Weight in kgs
GROUP-RD GROUP-RL
No of
Patients
( N )
Percentage
( % )
No of
Patients
( N )
Percentage
( % )
50 – 60 6 20.00 10 33.33
61 – 70 7 23.33 12 40.00
71 – 80 16 53.33 8 26.67
81- 90 1 3.33 0 0.00
TOTAL 30 100 30 100
Chi square
value 5.98
p-value 0.11
Significant Not  Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
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Mean Weight (Kg)
Group Mean Standard Deviation
GROUP-RD 70.60 9.18
GROUP-RL 67.47 8.22
t-value 1.39
p-value 0.77
Significant Not Significant
The mean weight distribution of the two groups are similar.
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TABLE-4 : Height Distribution
Height in cms
GROUP-RD GROUP-RL
No of
Patients
( N )
Percentage
( % )
No of
Patients
( N )
Percentage
( % )
151 – 160 3 10.00 4 13.33
161 – 170 12 40.00 19 63.34
171 – 180 15 50.00 7 23.33
TOTAL 30 100 30 100
Chi square
value 4.63
p-value 0.10
Significant Not  Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
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Mean Height (cm)
Group Mean Standard Deviation
GROUP-RD 169.97 5.86
GROUP-RL 168.20 5.02
t-value 1.25
p-value 0.22
Significant Not Significant
The mean height distribution of the two groups are similar.
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TABLE-5 :  Body Mass Index (Mean)
Group Mean Standard Deviation
GROUP-RD 24.38 2.60
GROUP-RL 23.78 2.09
t-value 0.98
p-value 0.33
Significant Not Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
The BMI of both the groups were similar in distribution.
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TABLE-6 : ASA Distribution
ASA
GROUP-RD GROUP-RL
No of
Patients
( N )
Percentage
( % )
No of
Patients
( N )
Percentage
( % )
I 21 70.00 27 90.00
II 9 30.00 3 10.00
TOTAL 30 100 30 100
Chi square
value 3.75
p-value 0.05
Significant Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
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TABLE-7 : Type of Surgery
Surgery
GROUP-RD GROUP-RL
No of
Patients
( N )
Percentage
( % )
No of
Patients
( N )
Percentage
( % )
DIST  RADIUS 7 23.33 7 23.33
ELBOW 3 10.00 2 6.68
FOREARM 5 16.67 4 13.33
HAND 8 26.67 12 40.00
RADIUS 3 10.00 1 3.33
ULNAR 0 0.00 1 3.33
WRIST 4 13.33 3 10.00
TOTAL 30 100 30 100
Chi square value 3.25
p-value 0.78
Significant Not Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
Higher percentages of surgeries were done in the hand and distal
radius in both the groups.
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TABLE-8 : PULSE RATE
GROUP-RD GROUP-RL t-
value p-value SignificantMean Sd Mean Sd
PRE 79.40 7.81 80.47 8.80 0.50 0.62 NS
0 Mint 78.00 6.87 81.00 7.53 1.61 0.11 NS
15 Mint 75.80 7.90 83.27 7.02 3.87 0.000 Significant
30 Mint 71.87 8.71 84.80 6.72 6.44 0.000 Significant
45 Mint 69.27 7.82 85.27 7.23 8.23 0.000 Significant
60 Mint 68.87 7.98 84.13 6.45 8.15 0.000 Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
The pulse rate showed statistically significant reduction in the
dexmedetomidine group starting at 15th minute but without requiring
any anti-cholinergics.
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TABLE-9 : SYSTOLIC BLOOD PRESSURE
GROUP-RD GROUP-RL
t-value p-value Significant
Mean Sd Mean Sd
PRE 118.33 12.69 117.53 12.61 0.25 0.81 NS
0 Mint 109.20 20.56 120.20 11.29 2.57 0.01 Significant
15 Mint 109.07 7.08 122.60 11.68 5.43 0.000 Significant
30 Mint 108.33 8.52 124.33 10.82 6.37 0.000 Significant
45 Mint 106.40 6.90 124.80 9.58 8.54 0.000 Significant
60 Mint 107.80 7.58 125.27 8.97 8.15 0.00 Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
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TABLE-10 : DIASTOLIC BLOOD PRESSURE
GROUP-RD GROUP-RL
t-value p-value Significant
Mean Sd Mean Sd
PRE 76.33 10.98 77.20 12.01 0.29 0.77 NS
0 Mint 74.13 8.53 80.60 9.12 2.84 0.01 Significant
15 Mint 71.67 8.98 82.40 10.14 4.34 0.000 Significant
30 Mint 69.20 8.95 84.73 10.29 6.24 0.000 Significant
45 Mint 67.20 6.49 83.80 7.80 8.96 0.000 Significant
60 Mint 67.80 7.01 86.20 8.23 9.32 0.000 Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
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TABLE-11 : MEAN ARTERY PRESSURE
GROUP-RD GROUP-RL
t-value p-value Significant
Mean Sd Mean Sd
PRE 90.33 11.39 90.64 12.06 0.10 0.92 NS
0 Mint 85.82 10.64 93.80 9.61 3.05 0.003 Significant
15 Mint 84.13 7.82 95.80 10.30 4.94 0.000 Significant
30 Mint 82.24 8.55 97.93 10.15 6.48 0.000 Significant
45 Mint 80.27 6.39 97.47 8.16 9.09 0.000 Significant
60 Mint 81.13 6.94 99.22 8.10 9.29 0.000 Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
The mean arterial pressure showed a significant reduction in the
dexmedetomidine group starting from 15th minute in comparison with
the control group without requiring treatment.
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TABLE-12 : SPO2
GROUP-RD GROUP-RL
t-value p-value Significant
Mean Sd Mean Sd
PRE 99.97 0.18 100.00 0.00 1.00 0.32 NS
0 Mint 100.00 0.00 100.00 0.00
15 Mint 100.00 0.00 100.00 0.00
30 Mint 100.00 0.00 99.97 0.18 1.00 0.32 NS
45 Mint 100.00 0.00 100.00 0.00
60 Mint 100.00 0.00 100.00 0.00
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
No significant difference in SpO2 occurs between the two groups.
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TABLE-13 : ONSET OF MOTOR BLOCK
GROUP-RD GROUP-RL
t-value p-value Significant
Mean Sd Mean Sd
Motor 12.23 1.85 18.77 1.22 16.13 0.000 Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
The mean onset time of motor block in the dexmedetomidine
group was 12.23 ± 1.85 minutes and was found to be significantly
earlier than the local anaesthetic group.
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TABLE-14 : ONSET OF SENSORY BLOCK
GROUP-RD GROUP-RL t-
value
p-
value
Significant
Mean Sd Mean Sd
Sensory 9.37 1.10 15.83 1.18 22.01 0.000 Significant
GROUP RD – Dexmedetomidine group
GROUP RL – Local anaesthetic group
The mean onset time of sensory block in the dexmedetomidine
group was 9.37 ± 1.10 minutes and was found to be significantly earlier
than the local anaesthetic group.
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TABLE-15 : DURATION OF ANALGESIA
GROUP-RD GROUP-RL t-
value
p-
value
Significant
Mean Sd Mean Sd
Analgesia 16.53 1.41 9.70 1.44 18.57 0.000 Significant
GROUP RD – Dexmedetomidine group
    GROUP RL – Local anaesthetic group
The mean duration of analgesia in the dexmedetomidine group
was 16.53 ± 1.41 hours and was found to be significantly longer than the
local anaesthetic group.
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TABLE-16 : Visual Analog Scale Score 0 – 4 HOURS
GROUP-RD GROUP-RL
Number Percentage Number Percentage
V0 30 100 28 93.33
V2 0 0 2 6.67
All the patients in the dexmedetomidine group had a Visual
Analog Scale score of 0(no pain) at the end of 4 hours whereas only 28
patients in the control group had a VAS score of 0 and two patients had
a VAS score of 2 indicating mild pain requiring no treatment.
TABLE-17 : 4 – 8 HOURS
GROUP-RD GROUP-RL
Number Percentage Number Percentage
V0 30 100 5 16.67
V2 0 0 23 76.67
V4 0 0 2 6.67
All the patients in the dexmedetomidine group had a Visual
Analog Scale score of 0(no pain) at the end of 8 hours whereas only five
patients in the control group had a VAS score of 0, twenty three patients
had a VAS score of 2 and two patients had a VAS score of 4(moderate
pain) that required treatment.
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TABLE-18 : 8 – 12 HOURS
GROUP-RD GROUP-RL
Number Percentage Number Percentage
V0 23 76.67 0 0
V2 7 23.33 5 16.67
V4 0 0 25 83.33
Twenty  three  patients  had  a  VAS  score  of  0  and  seven  patients
had a VAS score of 2(mild pain) in the dexmedetomidine group whereas
in the control group five patients had a VAS score of 2 and twenty five
patients had a VAS score of 4(moderate pain) requiring treatment at the
end of 12 hours.
TABLE-19 : 12 – 16 HOURS
GROUP-RD GROUP-RL
Number Percentage Number Percentage
V2 23 76.67 0 0
V4 7 23.33 30 100
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Now at the end of 16 hours, in the dexmedetomidine group still
twenty three patients had a VAS score of 2 and only seven patients had
a VAS score 4 requiring treatment. In the control group, all the thirty
patients had a VAS score of 4 requiring treatment.
TABLE-20 : 16 – 20 HOURS
GROUP-RD GROUP-RL
Number Percentage Number Percentage
V4 30 100 30 100
At the end of 20 hours, all the patients in both the
dexmedetomidine group and the control group had a VAS score of 4
requiring treatment.
Discussion
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DISCUSSION
Axillary block is one of the most commonly performed regional
nerve block for upper limb surgeries. Adjuvants have been added to
local anaesthetic mixtures to fasten the onset of sensory and motor block
and to prolong the duration of anaesthesia.
Alpha – 2 agonists are a group of recently discovered drugs. Two
drugs have been identified – clonidine and dexmedetomidine.
Dexmedetomidine has recently been approved for the usage of sedation
in patients in the Intensive Care Unit.
Dexmedetomidine is a more selective alpha – 2 agonist than
clonidine and has been found to prolong the effects of local anaesthetics
in epidural, intrathecal and peripheral nerve blocks with the advantages
of minimal respiratory depression and cardiovascular stability.
This prospective randomised controlled study conducted in 60
patients who underwent elective upper limb surgeries under axillary
plexus block demonstrated that dexmedetomidine in the dose of
50microgram when added to local anaesthetic mixture prolonged the
duration of analgesia significantly.
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Both the study and control groups were comparable in terms of
age, weight, height and BMI. The mean age of the patients in the
dexmedetomidine group was 37.6 ± 10.07 years. The mean age of the
patients in the control group was 33.13 ± 9.99 years. The mean body
mass index of the patients in the dexmedetomidine was 24.38 ± 2.6. The
mean body mass index of the patients in the control group was 23.78 ±
2.09. The variables were compared using independent sample test and
Levene’s test for the equality of variances and p value was found to be
not significant.
The mean arterial pressure of the patients in the dexmedetomidine
group was 80.27 ± 6.39 mmHg whereas the mean arterial pressure in the
control group was 97.47 ± 8.16 mmHg at the 45th minute. The mean
pulse rate of the patients in the dexmedetomidine group was around
70 bpm  in the dexmedetomidine group and around 85 bpm in the
control group but none of the patients required atropine. Statistical
analysis of the mean arterial pressure and mean pulse rate was done and
the p value was found to be significant.
The grades of sensory and motor block were checked every
5minutes after performance of the axillary block using pin prick and
Modified Bromage Scale respectively. The onset time of sensory and
87
motor blockade is defined as the time interval between the end of local
anaesthetic injection and
? Loss of sensation to pin prick (sensory score – 1)
? Paresis  (motor  scale  –  1)  in  the  distribution  of  all
peripheral nerves respectively.
The onset time of sensory block in the dexmedetomidine group
was found to be 9.37 ± 1.7 minutes whereas in the control group it was
found to be 15.83 ± 1.18 minutes. The onset time of motor block in the
dexmedetomidine group was found to be 12.23 ± 1.85 minutes whereas
in the control group it was found to be 18.77 ± 1.22 minutes. On
statistical analysis by the independent sample test and the t test for
equality of means has showed a faster onset times of sensory and motor
block significantly with a p value of 0.0001***.
The patients were followed in the post-operative ward every 2
hours for the presence of pain by the Visual Analog Scale. The presence
of  VAS  score  4  is  taken  as  the  endpoint  of  analgesia.  The  duration  of
analgesia is taken as the time from the performance of the block till the
appearance of VAS score 4.
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The mean duration of analgesia in the dexmedetomidine group
was found to be 16.53 ± 1.41 hours whereas the mean duration of
analgesia in the control group was found to be 9.70 ± 1.44 hours. At the
16th hour  the  number  of  patients  with  a  VAS  score  of  4  in  the
dexmedetomidine group was 7 whereas in the control group all the 30
patients had a VAS score of 4. At the 20th hour all the 60 patients in both
the groups had a VAS score of 4.
Yu Zhang et al in their study of 45 patients had demonstrated
similar faster onset of sensory and motor block - 15.46 ± 3.67 minutes
and 18.54 ± 5.24 minutes respectively on addition of 50microgram of
dexmedetomidine to 0.33% ropivacaine. They also demonstrated
prolongation of the duration of sensory and motor block - 804.00 ±
340.00 minutes and 737.73 ± 135.99 minutes respectively. The
incidence of bradycardia and hypotension that required treatment was
higher when 100microgram of dexmedetomidine was added to
ropivacaine as compared to 50microgram of dexmedetomidine added to
ropivacaine. Hence in our study we decided to add a low dose of
dexmedetomidine to the local anaesthetic mixture to produce the desired
response with minimal side effects. In our study we added
dexmedetomidine to local anaesthetic mixture of bupivacaine and
lignocaine with adrenaline and obtained comparable results.
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Kenan Kaygusuz et al in their study of 60 patients demonstrated
that the onset time of sensory and motor block in the dexmedetomidine
group was found to be 7.75 minutes and 14.25 minutes respectively and
was earlier than the control group. The duration of analgesia in this
study was found to be 924.15 minutes and was comparable to our study.
None of the patients who developed bradycardia, hypotension or
hypertension required treatment, which was similar to our study.
Imasogie N in his study compared the ultrasound guided axillary
plexus block using 2 point versus 4 point injections and concluded that
the 2 point injection was faster to administer but the block success rate
was similar in both the groups. In our study we performed the axillary
plexus block using the 2 point injection technique.
Saumya Biswas evaluated the addition of dexmedetomidine to
levobupivacaine in supraclavicular plexus block and concluded that the
duration of sensory and motor block was significantly longer in the
dexmedetomidine group. In our study we added dexmedetomidine to the
local anaesthetic mixture of bupivacaine plus lignocaine with
adrenaline.
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All the patients in our study both study and control groups were
monitored in the post-operative ward and were given supplemental
oxygen at the rate of 2litres/min. Dexmedetomidine has the unique
property in causing arousable sedation without any respiratory
depression.
Conclusion
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CONCLUSION
Dexmedetomidine in the dose of 50microgran when added as an
adjuvant to local anaesthetic mixture in axillary plexus block had a
faster onset of sensory and motor block(9.37 ± 1.1 and 12.23 ± 1.85
minutes) and significantly prolonged the duration of analgesia(16.53 ±
1.41 hours). They caused a minimal decrease in the mean arterial
pressure and heart rate which did not warrant treatment.
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Annexures
PROFORMA
Name of the patient: Age:
Sex: Weight:
Insurance No: OT:
Diagnosis: Duration of Procedure:
Surgeon: Anaesthetist:
PREOPERATIVE DETAILS
ASA GRADE:
VITALS:
BP
Pulse
rate
Resp.
rate
SpO2 Temp ECG Xray
Hb RBS RFT LFT Others
Onset of
sensory block
Onset of
motor block
Duration of
analgesia
SIGNATURE OF INVESTIGATOR SIGNATURE OF PATIENT
WITNESS:
PATIENT CONSENT FORM
STUDY TITLE: Prospective randomized controlled study evaluating
dexmedetomidine as an adjuvant added to a local anaesthetic mixture
of bupivacaine, lignocaine with adrenaline in axillary plexus block as
compared to axillary plexus block with local anaesthetic mixture
alone.
STUDY CENTRE:  ESIC MEDICAL COLLEGE & PGIMSR,
 KK NAGAR, CHENNAI – 78.
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I confirm that I have understood the purpose of procedure for the
above study. I have the opportunity to ask the question and all my
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I have been explained about the pitfall in the procedure. I have
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technique. I understand that my participation in the study is voluntary
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released to third parties or published, unless as required under the law.
I agree not to restrict the use of any data or results that arise from the
study.
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approved technique. This may help in future research in the field of
anaesthesia. I consent to undergo this procedure.
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GROUPS:
GROUP RD - Dexmedetomidine group
GROUP RL - Local anaesthetic group
PARAMETERS:
BMI - Body mass index
PR - Pulse rate
SYS - Systolic blood pressure
DIA - Diastolic blood pressure
MAP - Mean arterial pressure
ON_SB - Onset of sensory blockade
ON_MB - Onset of motor blockade
DUR - Duration of analgesia
V0 - VAS score of 0
V2 - VAS score of 2
V4 - VAS score of 4
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